HUDDINGE, Sweden, April 9, 2002 (PRIMEZONE) -- At today's Annual General Meeting of Tripep AB (publ), the President reported on the past year and on the development of Tripep's research projects. A new business plan has been drawn up that will focus on three business areas:
-- continued research and development of GPG, (but with more tangible
objectives than before,
-- pre-clinical research focused on the development of therapeutic
and prophylactic HIV and Hepatitis C vaccines, and the RAS
(technology platform,
-- acquisition of pharmaceutical projects at the clinical phase.
Tripep has around SEK 100 million to use for this purpose.
"If 2001 was a decisive year, then I'd like to call 2002, a year of possibilities - a year in which Tripep shows that a biotech research company can rally even after a serious setback," said Hans Moller.
A decision was made to follow the Board's proposal not to pay a dividend for the 2002 financial year.
Harry Faulkner, Lars Lindegren, Johan Malmsten, Anders Vahlne and Hans Moller were re-elected to the Board.
The AGM decided on a reduction of SEK 140,000,000 in the share premium reserve to SEK 2,392,363 in accordance with chapter 12:4, paragraph 3, item 3 of the Swedish Companies Act. The funds will be transferred to non-restricted equity. The decision of the AGM is conditional on the court granting permission for this reduction in accordance with the above regulation.
At the Board meeting following election in connection with the AGM, Harry Faulkner was re-elected as Chairman of the Board.
This information was brought to you by Waymaker http://www.waymaker.net